Added to YB: 2026-07-14
Pitch date: 2026-07-10
TLSA [neutral]
Tiziana Life Sciences Ltd
+9.02%
current return
Author Info
No bio for this author
Company Info
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally.
Market Cap
$159.0M
Pitch Price
$1.22
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.44
P/E
-7.89
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
TLSA: Not To Be Confused With TSLA
TLSA (overview): Single-asset biotech; nasal anti-CD3 antibody foralumab for non-active SPMS, P2a data late Q3-Q4 2026. Bear: drug can't cross BBB, <1% nasal bioavailability, PIRA biology sits behind intact barrier. Treg 'tissue A→B' mechanism has failed confirmatory trials since 1990s (same investigator). EAP 'efficacy' data meaningless vs placebo base rates. INFORM-MS underpowered (n=16/arm), primary endpoints are safety/PET, likely null on clinical measures.
Read full article (14 min)